InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: None

Wednesday, 10/02/2019 6:09:07 PM

Wednesday, October 02, 2019 6:09:07 PM

Post# of 108192
All it's gonna take for ADXS is updated survival data from the metastatic castration resistant prostate cancer study. If that's good? The stock price could easily triple or quadruple. Why? Because Xtandi and Zytiga are king in this area. If lm plus Keytruda beats mOS timeframe on both of these drugs, the stock will skyrocket.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News